EHA Mentorship Program

A new, career-focused program that provides individual mentoring support for early and mid-career clinicians and researchers in hematology. The call for mentees closed on February 20, 2025.

Patient organizations

EHA greatly values the collaboration with patient organizations in a growing number of areas, from joint advocacy and a strong presence at the EHA Annual Congress – with a prominent place for the EHA-Patient Joint Symposium on policy and regulatory…

EHA Statement on COVID-19 Vaccines

EHA statement on coronavirus (COVID-19)

The European Hematology Association (EHA) closely monitors the latest developments on the spreading of the Coronavirus (COVID-19).

New HemaSphere publication on IVDR implementation

The In Vitro Diagnostic medical devices Regulation (IVDR), which came in to force in May 2022 with the objective of safeguarding the quality and safety of diagnostic tests in the EU, has a major impact on commercially available IVDs (CEIVDs) and…

EHA statement on coronavirus (COVID-19)

The European Hematology Association (EHA) closely monitors the latest developments on the spreading of the Coronavirus (COVID-19).

EHA undersigns Manifesto on Treatment Optimization

EHA has given its formal endorsement to the “Manifesto for a new approach for better medicine in Europe: Establishing Treatment Optimization as part of personalized medicine development”.

Position of EHA on Research Funding

 

The challenge
The cost of biomedical research is great, but the cost of disease is immense. An ageing population and expensive innovations in medicine put an increasing burden on already stressed healthcare budgets.

Position of EHA on Clinical Trials

 

The challenge
In Europe, the number of clinical trials is steadily decreasing. From 2007 to 2010, their number has decreased by some 20 percent from 5,028 to 4,193.